Denominazione Comune Italiana

Denominazione Comune Italiana (DCI) is the official nomenclature used in Italy for the naming of medicinal products. The DCI is equivalent to the International Nonproprietary Name (INN) system used internationally, but specifically tailored to the Italian language and medical context.

Overview

The DCI is established and maintained by the Italian Medicines Agency (AIFA), the national authority responsible for drug regulation in Italy. The DCI is used in the labeling, prescription, and dispensing of medicines, and is intended to provide a clear, standardized way of identifying each medicinal product.

Each DCI name is unique and is intended to be unambiguous in its identification of a particular medicinal product. The DCI name typically includes the generic name of the drug, its dosage form, and its strength.

Purpose and Use

The DCI serves several important functions in the Italian healthcare system. It facilitates clear communication among healthcare professionals, helps to prevent medication errors, and supports the rational use of medicines.

In addition, the DCI is used in the pricing and reimbursement of medicines in Italy. The AIFA uses the DCI to establish the reference price for each medicinal product, which is the maximum price that the National Health Service (NHS) will reimburse for that product.

See Also

• Pharmacopoeia
• Drug nomenclature
• Anatomical Therapeutic Chemical Classification System

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian